Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

Akero Therapeutics Akero Therapeutics ( AKRO ) announced publication in The Lancet Gastroenterology & Hepatology of results from the HARMONY Phase 2b trial in nonalcoholic steatohepatitis ( NASH ). The paper, which is available online, provides data on the safety,...

October 4, 2023

Valneva SE and Pfizer Inc Announce Further Positive Results in Preventing Lyme Disease

Valneva SE and Pfizer Inc Announced More Positive Trial Results of VLA15 for Lyme Disease What is Lyme Disease? What is the vaccine? What is the importance of the vaccine and the company that created it? Lyme disease is...

September 30, 2021

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

Apellis Pharmaceuticals Launch Update of SYFOVRE ® On October 5, 2023, Apellis Pharmaceuticals ( APLS ) provided an update on the launch of its product SYFOVRE® (pegcetacoplan injection) for geographic atrophy ( GA ) secondary to age-related macular degeneration ( AMD...

October 6, 2023

Merck and Ridgeback Biotherapeutics Announced Successful Phase 3 Trial Results of Molnupiravir for Mild or Moderate COVID-19

Merck and Ridgeback Biotherapeutics COVID-19 News Merck ( MRK ) and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801) - an investigational oral antiviral medicine, has significantly reduced the risk of hospitalization or death at a planned interim analysis of the...

October 1, 2021

Please Don't Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Investor webcast on Tuesday, October 10th at 8:00 a.m. ET to present clinical data. Akero Therapeutics ( AKRO )...

October 9, 2023

Eli Lilly Gene Therapy Restores Patient Hearing

Akous Inc to Present at the Association for Research in Otolaryngology Akouos, Inc. - a wholly owned subsidiary of Eli Lilly and Company ( LLY ) announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which restored the...

January 24, 2024

Atea Pharmaceuticals and Xenon Pharmaceuticals: Two Clinical-Stage Firms That Rallied Instead of Crashing Yesterday

Two Clinical-Stage Firms Rallied Yesterday On a day when the Stock Market was crushed, taking down with it shareholders’ money for no reason other than the self-serving untouchable agendas, two small biotechnology companies staged rallies. Atea Pharmaceuticals and Xenon Pharmaceuticals...

October 5, 2021

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

Inovio Receives FDA Feedback for INO-3107 INOVIO ( INO ) - a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced that it received feedback from...

October 11, 2023

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 - Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Intellia Therapeutics Receives PRIME Designation from EMA Intellia Therapeutics ( NTLA ) announced that the European Medicines Agency ( EMA ) has granted Priority Medicine ( PRIME ) designation to its product NTLA-2002. As we already know, NTLA-2002 is an...

October 14, 2023

Apellis Announces Negative CHMP Opinion on Pegcetacoplan for GA in the EU and Its Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals Negative CHMP Opinion Apellis Pharmaceuticals ( APLS ) announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application ( MAA...

January 27, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024